Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M412145200 on April 22, 2005

J. Biol. Chem., Vol. 280, Issue 25, 23615-23621, June 24, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/25/23615    most recent
M412145200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poon, C. J.
Right arrow Articles by Fosang, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poon, C. J.
Right arrow Articles by Fosang, A. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

N-Linked Keratan Sulfate in the Aggrecan Interglobular Domain Potentiates Aggrecanase Activity*

Christopher J. Poon{ddagger}§, Anna H. Plaas¶, Doug R. Keene||, David J. McQuillan**, Karena Last{ddagger}, and Amanda J. Fosang{ddagger}{ddagger}{ddagger}

From the {ddagger}Department of Paediatrics, University of Melbourne and Murdoch Childrens Research Institute, Arthritis Research Group, Royal Children's Hospital, Parkville, Victoria 3052, Australia, Department of Internal Medicine, University of South Florida, Tampa, Florida 33602, ||Shriners Hospital for Children, Portland, Oregon 97239, and **LifeCell Corporation, Branchburg, New Jersey 08876

Keratan sulfate is thought to influence the cleavage of aggrecan by metalloenzymes. We have therefore produced a recombinant substrate, substituted with keratan sulfate, suitable for the study of aggrecanolysis in vitro. Recombinant human G1-G2 was produced in primary bovine keratocytes using a vaccinia virus expression system. Following purification and digestion with specific hydrolases, fluorophore-assisted carbohydrate electrophoresis was used to confirm the presence of the monosulfated Gal-GlcNAc6S and GlcNAc6s-Gal disaccharides and the disulfated Gal6S-GlcNAc6S disaccharides of keratan sulfate. Negligible amounts of fucose or sialic acid were detected, and the level of unsulfated disaccharides was minimal. Treatment with keratanases reduced the size of the recombinant G1-G2 by ~5 kDa on SDS-PAGE. Treatment with N-glycosidase F also reduced the size of G1-G2 by ~5 kDa and substantially reduced G1-G2 immunoreactivity with monoclonal antibody 5-D-4, indicating that keratan sulfate on the recombinant protein is N-linked. Cleavage of G1-G2 by aggrecanase was markedly reduced when keratan sulfate chains were removed by treatment with keratanase, keratanase II, endo-{beta}-galactosidase, or N-glycosidase F. These results indicate that modification of oligosaccharides in the aggrecan interglobular domain with keratan sulfate, most likely at asparagine residue 368, potentiates aggrecanase activity in this part of the core protein.


Received for publication, October 27, 2004 , and in revised form, April 12, 2005.

* This work was supported in part by funds from the National Health and Medical Research Council (Australia) and the Mizutani Foundation for Glycoscience, Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by Eileen Urquhart and Frank G. Spurway Scholarships from the Arthritis Foundation of Australia.

{ddagger}{ddagger} To whom correspondence should be addressed: Dept. of Paediatrics, University of Melbourne and Murdoch Childrens Research Institute, Arthritis Research Group, Royal Children's Hospital, Flemminton Rd. Parkville, Victoria 3052, Australia. Tel.: 61-3-9345-6628; Fax: 61-3-9345-7997; E-mail: amanda.fosang{at}mcri.edu.au.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. Z. Ilic, C. J. East, F. M. Rogerson, A. J. Fosang, and C. J. Handley
Distinguishing Aggrecan Loss from Aggrecan Proteolysis in ADAMTS-4 and ADAMTS-5 Single and Double Deficient Mice
J. Biol. Chem., December 28, 2007; 282(52): 37420 - 37428.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. J. Wayne, S.-J. Deng, A. Amour, S. Borman, R. Matico, H. L. Carter, and G. Murphy
TIMP-3 Inhibition of ADAMTS-4 (Aggrecanase-1) Is Modulated by Interactions between Aggrecan and the C-terminal Domain of ADAMTS-4
J. Biol. Chem., July 20, 2007; 282(29): 20991 - 20998.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement